BPC-157 is explored for tendon, ligament and gut recovery. Laboratory work examines repair signaling; clinic reports and community accounts describe pain and movement changes.
Research focus: Tissue recovery, joint comfort and gut-related questions.
Choose a compound to open its research, documentation and calculator.
No FDA-approved drug product for this catalog material. Compounding eligibility and approval are separate questions.
Official source ↗IV/IM animal data. A four-hour community value is not verified as a human subcutaneous half-life.
Half-life describes concentration falling by half. It does not set a dosing interval, a storage period or a drug-test detection window.
Kinetics source ↗PeptIQ lists bacteriostatic water for repeated-vial workflows. That preference is not a compatibility study for a particular formulation; the actual product or pharmacy instructions determine the liquid.
Bacteriostatic water contains a preservative; plain sterile water does not. Preservative presence does not by itself establish compatibility or a mixed medicine’s usable period.
Preparation source ↗Changes in symptoms, laboratory cells and animal healing are different outcomes. The selected studies do not establish an effective human injury-treatment regimen or a typical before-and-after result.
Check that a source concerns the same molecule, formulation, route and population. A study of cells, animals or a different product cannot confirm the contents of a vial.
Tendon-cell experiments and small human reports, with community experiences shown separately.
BPC-157 is a short synthetic peptide investigated for effects on tissue repair. In one rat-tendon experiment, researchers observed cell migration and stress survival, with changes in FAK–paxillin signaling. That is a possible mechanism to investigate, rather than a measured recovery outcome in people. Explore the tendon-cell experiment →
These are selected public accounts, not a representative sample. Product identity, diagnoses and measurements are unverified. Posts cannot establish a response rate, an average recovery time or whether BPC-157 caused a change.
The Reddit Answers overview ↗ is AI-generated. We followed its original discussions so you can compare the accounts and their context directly.
One author describes easier movement and less pain after several weeks, later clarifying that they used an oral product. A different commenter describes immediate relief, while also discussing TB-500 and GHK-Cu. These are different exposures and timelines.
Read the original discussion ↗A three-month account describes a positive overall experience with separate BPC-157 and TB-500, but incomplete improvement in chronic problems. A reply reports no benefit. Combining those experiences into a single “success rate” would hide their differences.
Read the account and replies ↗Another author describes initial elbow relief followed by anxiety, shaking, a racing heart and near-fainting, then stopping use. They also note prior near-fainting episodes and uncertainty about the product. The account cannot determine the cause or how often this occurs.
Read the adverse-experience account ↗Pain ratings, movement and daily activities describe how someone feels or functions. They are valuable observations, especially when measured consistently over time.
This is a different claim. The selected forum accounts do not establish tendon, ligament or cartilage repair with standardized follow-up imaging or a comparison group.
Read the timeline with the context: injury diagnosis, baseline function, rehabilitation, rest, surgery, other medicines and stacked compounds can all change the interpretation. A before-and-after photo alone cannot isolate a peptide’s effect.
Compare the published studies ↓Other names you may encounter: BPC157.
Learn to read a study →Each entry keeps one schedule’s amount, frequency and cycle together. Community references, individual reports, clinical trials and prescription products describe different kinds of use. A missing duration or break stays marked as not reported.
Amounts describe mass in mg or mcg. Syringe units describe volume and depend on concentration. A cycle break is different from days off within a week.
Choose an option to explore its amounts, timing and cycle.
A 500 mcg daily total divided in two is 250 mcg per administration. Daily-total and per-injection amounts are different.
Each four-week block contains 20 injections. The two days off each week are separate from the break after three blocks.
Separate TB-500 was also used. Later amounts appear in the longer reported-use entry below.
Amount increased after about 15 days. Separate TB-500 was also used; this entry describes the BPC-157 component.
Community identifies source origin. It does not certify independent funding, medical credentials or the strength of a claim. Source types distinguish published reports, professional explanations and public discussions.
Explore reports, explanations and discussions from medical practices, researchers, suppliers and community members. The badges identify the source’s origin and evidence type.
How to read these source labels →The daily-total table and once-or-twice-daily prose are not fully consistent. These descriptions are not trial-validated schedules.
Source relationship: Commercial clinic discussing services and proposed uses.
A clinic overview compares oral and injected BPC-157 and discusses Wolverine and other pairings. Its amounts appear in the BPC-157 dosage snapshot.
Clinic explanation · commercial treatment provider
The introductory frequency and cycle wording differs from the detailed schedule. The page does not establish that intermittent use matches daily use.
Source relationship: Commercial clinic offering the treatments described; inclusion is not an endorsement.
The detailed schedule describes once-daily use on five days per week. The article also discusses individualized Wolverine pairings.
Clinic explanation · commercial treatment provider
Selected forum discussion, not a clinical dataset. Diagnosis, product identity and outcomes are unverified. Symptom improvement does not demonstrate tissue repair or isolate a peptide effect from rehabilitation and natural recovery.
Source relationship: Public pseudonymous accounts; medical credentials, funding and commercial relationships are not verified.
The author reports less pain and easier movement after several weeks, and clarifies in replies that they used an oral product. Other commenters describe injected products, combinations and different experiences.
Self-report · routes and combinations differ · no standardized healing measurements
Neither the author’s positive account nor a negative reply estimates the likelihood of benefit. Concurrent TB-500 and other factors confound attribution. Self-described medical connections do not verify clinical credentials or a supervised protocol.
Source relationship: Public pseudonymous accounts. Funding, credentials and conflicts are unverified; inclusion is not a supplier endorsement.
The author describes benefits and incomplete chronic improvement while using separate BPC-157 and TB-500. A directly linked reply reports no benefit. The post also discusses changing amounts and product-quality concerns.
Self-report · two compounds · mixed responses · no control group
A temporal association does not establish the cause or frequency of an adverse effect. No independently reviewed medical record, verified product analysis or comparison group is supplied here. It is not proof of a specific caffeine or alcohol interaction.
Source relationship: Public pseudonymous account; clinical credentials, funding and conflicts are not verified.
The author reports initial elbow relief, followed by anxiety and later shaking, a racing heart and near-fainting. They stopped use and describe uncertainty about the product and prior near-fainting episodes.
Self-report · adverse symptoms · causality and product identity uncertain
No control group, randomization or validated outcome scale; the combination subgroup had only four people. Reported improvement cannot establish cause, safety or superiority of the combination. The abstract names thymosin beta-4, not an identified TB-500 fragment. It does not validate a subcutaneous Wolverine schedule.
Source relationship: Report from a treating medical practice. Funding and conflicts require checking in the full paper; independent funding is not established here.
This retrospective report describes knee-joint injections and telephone follow-up for 16 patients. Twelve received BPC-157 alone; four received BPC-157 with thymosin beta-4. Three of those four reported pain improvement.
Retrospective · no control group · thymosin beta-4 identity, not verified TB-500
A peptide name and vial mass cannot determine a compatible diluent, powder displacement, storage temperature or discard date. Follow the exact product’s instructions and your pharmacist’s directions.
The injection guide concerns clinician-prescribed subcutaneous medicines; it does not establish that a research-labeled material can be injected.
Start with the formulation: dry powder, prepared solution, pen, tablet and topical product can have different instructions.
FDA’s review distinguishes BPC-157 free base from BPC-157 acetate. An oral capsule, spray, injected preparation and multi-component blend raise different formulation questions; a forum nickname does not specify those details.
A purity percentage does not establish sterility, endotoxin control or absence of particles. FDA’s assessment identifies these as separate quality considerations for injectable products, alongside peptide impurities and aggregation.
The reviewed sources do not provide a validated universal BPC-157 diluent, mixing volume, storage period or discard date. A calculator can show concentration arithmetic, but those preparation details require documentation for the exact formulation.
Read the FDA formulation and quality assessment ↗General health habits and consistent observations help you assess changes. They are not evidence that a peptide’s effects will be amplified.
A diagnosis, progressive rehabilitation and an appropriate return to activity help put pain and function changes in context.
NIAMS · injury treatment and recovery ↗Use a regular sleep/wake schedule and note changes in sleep quality alongside symptoms or training.
CDC · sleep habits ↗What to record: Record pain, movement, training load and rehabilitation together. Feeling less pain and demonstrating structural healing are different outcomes.
Check dates are editorial references, not a medical review certificate. Labels and evidence can change; consult the linked current document.
Clinic explainers describe practices and advertise services; they are not controlled clinical studies. Online guides may also promote commercial products or apps. Inclusion does not verify product contents or endorse a provider.
Dr. Rogers’ route table labels its range as a daily total, while some prose uses once-or-twice-daily wording. Perfect B’s opening paragraph also differs from its detailed once-daily, five-on/two-off description. We preserve those differences rather than turn them into a single consensus.
Daily total versus each administration. A reported total of 500 mcg split into two equal amounts means 250 mcg each time. It does not mean 500 mcg twice. Dr. Rogers’ broader overview mentions 200–500 mcg daily; its subcutaneous table narrows that to 250–500 mcg. Compare the clinic’s table and text ↗
Route and intended target. These pages associate subcutaneous use with musculoskeletal concerns and oral or sublingual products with gut concerns. PeptideSchedule describes fasted oral use, whereas Dr. Rogers’ oral table lists a lower 200–500 mcg daily range. These are reported practices, not established treatment effects or equivalent formulations. Online route description ↗ · Clinic route comparison ↗
Days off are not the same as a break between cycles. Perfect B’s detailed example describes one administration per day on five days each week, a month of 20 administrations, and up to three cycles before a two-month break. That is one clinic’s account. InCare also describes 6–8-week tendon/joint cycles, alongside the shorter and longer examples above. Perfect B’s schedule ↗ · InCare’s cycle comparison ↗
These entries describe what individual posters say they used. They are not dose recommendations, tested starter regimens or evidence that daily and five-on/two-off schedules are equivalent. “Microdose” has no standardized meaning in these sources.
The original forum accounts add individual experiences to the clinic descriptions above.
The three-month author reports an early phase of 250 mcg BPC-157 daily, then higher amounts later, while also using separate TB-500. The experience cannot isolate BPC-157’s contribution.
Source: u/introverted-me ↗A commenter in the oral-product discussion describes 200 mcg daily on five days per week. This is a personal account; the studies selected here did not compare that pattern with uninterrupted daily use.
Source: u/DaCozPuddingPop in the replies ↗Route changes the question. The knee report used injections into a joint; the small safety pilot used intravenous infusions. Neither is a study of a home subcutaneous schedule, nor a demonstration that injecting close to an injury works better. Oral and injected products should not be treated as equivalent.
Common pairings. Wolverine pairs BPC-157 with TB-500, sometimes on different schedules when supplied separately. Dr. Rogers also discusses CJC-1295/Ipamorelin pairings; these are different stacks, not other names for Wolverine. Clinic’s stacking discussion ↗
Compare Wolverine’s reported component schedules →Headache, nausea, fatigue and mood changes appear in community or provider discussions, but dependable incidence rates and causality are not established. The adverse-experience account above includes anxiety and other symptoms.
FDA’s assessment identifies gaps in carcinogenicity testing. Angiogenesis findings from experimental models do not by themselves establish a human cancer risk or long-term safety. A cycle break is not evidence that these uncertainties disappear.
BPC-157 remains experimental, without an FDA-approved drug regimen. FDA has identified limited safety information and concerns about immunogenicity and product quality. It is also prohibited under WADA’s 2026 S0 category for athletes subject to those rules. FDA assessment ↗ · Anti-doping advisory ↗
Selected studies and clinical reports, with the question, context and limitations close at hand.
What cellular changes might help explain the interest in tendon research?
What did a small practice report about pain after joint injections?
What was observed during a very small, short-term intravenous pilot?
Opening values and worked examples illustrate arithmetic; they are not preparation instructions or recommended amounts. Selecting a compound labels the calculation and does not supply a dose or powder-volume correction.
Enter the documented vial mass, preparation information and target amount to see how mass and volume connect.
20 mg in an assumed final 1 mL gives 20 mg/mL. An entered 1 mg corresponds to 0.05 mL, or 5 U-100 units, with 20 theoretical portions before losses.
Estimate · assumes 1 mL added = total volume
1,000 mcg
Theoretical · before losses
0.2 mL
After 5 full doses
Illustration only · calculated value, without rounding
Saved calculations stay on this device.
Concentration = mass ÷ final volume
5 mg ÷ 1 mL = 5 mg/mLVolume = target mass ÷ concentration
1 mg ÷ 5 mg/mL = 0.2 mLU-100 markings = volume × 100
0.2 mL × 100 = 20 unitsComplete portions = floor(vial mass ÷ amount per portion).
Displayed numbers are rounded for readability; the calculation uses unrounded values.
Already have the concentration? Find the matching mL and U-100 syringe reading.
Need the concentration first? Use the Reconstitution tab.
5units
0.05 mL · 0.25 mg
0.25 mg ÷ 5 mg/mL = 0.05 mLU-100 units = mL × 100Example inputs are editable. The reading is calculated without rounding to a physical graduation.
Convert mass or liquid volume. U-100 markings always refer to a 100-units-per-mL scale.
1,000mcg
For mass → syringe volume, switch to Dosage and enter a concentration.